Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 4/20 | 0.53 |
| ▸ | MITF | O75030 | 2/20 | 0.53 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.53 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.49 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | NOS2 | P35228 | 2/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428592 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL12560610 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL6160911 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL6160913 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL18653617 | 0.84 | NPC1 (0.54) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL283337 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL283338 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL640709 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL24170743 | 0.81 | PKM (0.51) | KDM4EALDH1A1KMT2ANPC1RAB9A | |
| SCHEMBL2931559 | 0.81 | LMNA (0.54) | KDM4EALDH1A1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328232-A1 | ELECTROCHEMICAL BIOSENSOR, OR SENSING MEMBRANE FOR ELECTROCHEMICAL BIOSENSOR CONTAINING TRANSITION METAL COMPLEX OR OXIDATION-REDUCTION POLYMER | I-SENS, INC. (KR) | 2024-02-28 | — | — | EP | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691992-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11498936-B2 | Preparation of metal-pyridine derivative complexes for use in medical imaging | UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE (GB) | 2022-11-15 | — | — | US | disclosed |
| US-11498936-B2 | Preparation of metal-pyridine derivative complexes for use in medical imaging | UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE (GB) | 2022-11-15 | — | — | US | disclosed |
| EP-3724203-B1 | PREPARATION OF METAL-PYRIDINE DERIVATIVE COMPLEXES FOR USE IN MEDICAL IMAGING | UNIV OF NORTHUMBRIA AT NEWCASTLE (GB) | 2021-11-24 | — | — | EP | disclosed |
| EP-3724203-B1 | PREPARATION OF METAL-PYRIDINE DERIVATIVE COMPLEXES FOR USE IN MEDICAL IMAGING | UNIV OF NORTHUMBRIA AT NEWCASTLE (GB) | 2021-11-24 | — | — | EP | disclosed |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10961261-B2 | Oxaborole analogs and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200369698-A1 | Preparation of Metal-Pyridine Derivative Complexes for Use in Medical Imaging | UNIVERSITY OF NORTHUMBRIA AT NEWCASTLE (GB) | 2020-11-26 | — | — | US | disclosed |
| US-7105548-B2 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2006-09-12 | — | — | US | disclosed |
| EP-1458708-A4 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-6903085-B1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | ASTRAZENECA, AB (CH) | 2005-06-07 | — | — | US | disclosed |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-01-27 | — | — | US | disclosed |
| EP-1458708-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003051315-A2 | HETEROARYL SUBSTITUTED TRIAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| EP-1212299-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca UK Limited (GB) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001014333-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA UK LIMITED (GB) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691992-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | KDM4E 3901/4885ALDH1A1 486/4885KMT2A 4439/4885 |
| US-11498936-B2 | Preparation of metal-pyridine derivative complexes for use in medical imaging | MEN1, PDCD1, PDCD1LG2 | KDM4E 3041/4885ALDH1A1 1291/4885KMT2A 4100/4885 |
| US-20050020585-A1 | Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN3A | KDM4E 2329/4885ALDH1A1 2269/4885KMT2A 1013/4885 |
| US-20200369698-A1 | Preparation of Metal-Pyridine Derivative Complexes for Use in Medical Imaging | MEN1, PDCD1, PDCD1LG2 | KDM4E 3041/4885ALDH1A1 1291/4885KMT2A 4100/4885 |
| US-20210253605-A1 | NOVEL OXABOROLE ANALOGS AND USES THEREOF | OXA1L, AOX1, EPX | KDM4E 3884/4885ALDH1A1 626/4885KMT2A 4486/4885 |
| US-10961261-B2 | Oxaborole analogs and uses thereof | OXA1L, EPX, OAT | KDM4E 3901/4885ALDH1A1 486/4885KMT2A 4439/4885 |
| US-20050250792-A1 | Substituted piperidine compounds useful as modulators of chemokine receptor activity | CXCR4, CXCR1, CXCR3 | KDM4E 2699/4885ALDH1A1 1952/4885KMT2A 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.